Clinical Trial Update: A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial evaluated the analgesic efficacy and safety of ABT-639 versus placebo in diabetic neuropathic pain and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathic Pain

Drugs mentioned

• ABT-639

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Diabetic Neuropathic Pain | Phase 2 | Status: COMPLETED